PepGen Inc. (PEPG)
NASDAQ: PEPG · Real-Time Price · USD
1.550
-0.100 (-6.06%)
At close: May 15, 2026, 4:00 PM EDT
1.580
+0.030 (1.94%)
After-hours: May 15, 2026, 7:15 PM EDT
PepGen Employees
PepGen had 56 employees as of December 31, 2025. The number of employees decreased by 25 or -30.86% compared to the previous year.
Employees
56
Change
-25
Growth
-30.86%
Revenue / Employee
n/a
Profits / Employee
-$1,378,857
Market Cap
107.21M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 56 | -25 | -30.86% |
| Sep 30, 2025 | 57 | -19 | -25.00% |
| Jun 30, 2025 | 62 | -10 | -13.89% |
| Mar 31, 2025 | 79 | 14 | 21.54% |
| Dec 31, 2024 | 81 | 17 | 26.56% |
| Sep 30, 2024 | 76 | 13 | 20.63% |
| Jun 30, 2024 | 72 | 18 | 33.33% |
| Mar 31, 2024 | 65 | 16 | 32.65% |
| Dec 31, 2023 | 64 | 19 | 42.22% |
| Sep 30, 2023 | 63 | 23 | 57.50% |
| Jun 30, 2023 | 54 | 18 | 50.00% |
| Mar 31, 2023 | 49 | 18 | 58.06% |
| Dec 31, 2022 | 45 | 14 | 45.16% |
| Sep 30, 2022 | 40 | 17 | 73.91% |
| Jun 30, 2022 | 36 | 24 | 200.00% |
| Mar 31, 2022 | 31 | 19 | 158.33% |
| Dec 31, 2021 | 31 | - | - |
| Sep 30, 2021 | 23 | - | - |
| Jun 30, 2021 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cibus | 118 |
| Inovio Pharmaceuticals | 112 |
| enGene Therapeutics | 82 |
| Rani Therapeutics Holdings | 71 |
| Biomea Fusion | 41 |
| Cardiff Oncology | 31 |
| Oncolytics Biotech | 29 |
| Cognition Therapeutics | 14 |
PEPG News
- 2 days ago - PepGen price target lowered to $4 from $5 at Wedbush - TheFly
- 3 days ago - PepGen reports Q1 EPS (26c), consensus (31c) - TheFly
- 3 days ago - PepGen sees cash runway into 2H27 - TheFly
- 3 days ago - PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - Business Wire
- 6 weeks ago - PepGen Transcript: Study update - Transcripts
- 6 weeks ago - PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 6 weeks ago - PepGen down 46% at $2.30 after Phase 2 Freedom trial data - TheFly
- 6 weeks ago - PepGen Inc trading resumes - TheFly